Intrinsic Capital Partners
VC Fund
Philadelphia, United States
Intrinsic Capital Partners is a private equity fund dedicated to investing in promising growth businesses in the emerging legal cannabis industry. Their team has years of investment, pharmaceutical, regulatory, and deal structure experience. Along with our world class network of operating partners with decades of experience building businesses andbrands across healthcare and consumer industries, they are dedicated to creating value for portfolio company owners while generating superior returns for our fund investors.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 80%
- Fund size:
- $102M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Intrinsic Capital Partners invests in
Stages Intrinsic Capital Partners invests in
Countries Intrinsic Capital Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Series A
- $12M–$20M
Investment Focus
Industry
- Biotechnology 5 (50%)
- Health Care 3 (30%)
- Cannabis 2 (20%)
- SaaS 1 (10%)
- Farming 1 (10%)
Stage
- Series A 4 (40%)
- Venture - Series Unknown 2 (20%)
- Series B 1 (10%)
- Series D 1 (10%)
- Funding Round 1 (10%)
Country
- United States 5 (50%)
- Denmark 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Cornelius Merlini
Managing Partner & Founder
|
Managing Partner & Founder | Total investments: 1 | Find email | |
|
Gerald F Stahlecker
Partner & Founder
|
Partner & Founder | Total investments: 0 | Find email | |
|
Howard Goodwin
Partner & Founder
|
Partner & Founder | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Nalu Bio is a biotech company developing CBD (and cannabinoids) through chemistry (not plants), for companies who want pure and safe ingredients that are better for the planet. Ranked as the #1 CBD producer on the “google for ingredients.” Like plant-based meats, Nalu Bio will fundamentally disrupt CBD production with chemistry. Nalu Bio uses 700xless land, 70x less water, and 14x less energy to produce its cannabinoids while ensuring best-in-class purity and quality (0% THC, no chemicals, no pesticides) without the high capital investment costs of hemp extraction and biosynthesis. | $12M / Series A / Feb 28, 2023 | |
|
|
Nalu Bio is a biotech company developing CBD (and cannabinoids) through chemistry (not plants), for companies who want pure and safe ingredients that are better for the planet. Ranked as the #1 CBD producer on the “google for ingredients.” Like plant-based meats, Nalu Bio will fundamentally disrupt CBD production with chemistry. Nalu Bio uses 700xless land, 70x less water, and 14x less energy to produce its cannabinoids while ensuring best-in-class purity and quality (0% THC, no chemicals, no pesticides) without the high capital investment costs of hemp extraction and biosynthesis. | $12M / Series A / Feb 28, 2023 | |
|
|
QNTM Labs provides research, development, and regulatory compliance services for pharmaceutical companies. They improve transparency and access to robust scientific analysis, working with global researchers, API manufacturers, and pharmaceutical industry stakeholders through analytical testing, contract research, and clinical trial support. Theyoffer R&D testing, quality control testing, and contract research. | Series A / Nov 17, 2022 | |
|
|
Biopharmaceutical Research Company develops active pharmaceutical ingredients for plant therapeutics. The company focuses on the production of cannabis for researchers across the United States and the USDA-compliant THC testing of hemp. | $20M / Series A / Oct 04, 2022 | |
|
|
They use innovative agriculture technology to analyze and enhance cannabis. Their research team is led by expert plant scientist Dr. Stephanie Wedryk. | $9.8M / Nov 08, 2021 | |
|
|
They use innovative agriculture technology to analyze and enhance cannabis. Their research team is led by expert plant scientist Dr. Stephanie Wedryk. | $9.8M / Venture - Series Unknown / Nov 08, 2021 | |
|
|
Hound Labs is a breath technology company that has developed ultra-sensitive technology for non-invasive breath measurement. Utilizing this groundbreaking technology, the HOUND MARIJUANA BREATHALYZER is the world’s first breathalyzer to rapidly, accurately, and inexpensively measure recent marijuana use and alcohol in a person’s breath. The HOUNDBREATHALYZER is intended for law enforcement, employer, and insurance purposes only. Founded in 2014, the Oakland-based company was created by Dr. Mike Lynn, an ER physician, reserve deputy sheriff, and former venture capitalist, his co-founder, Mr. Kuni Oh, a patent attorney with a deep background in engineering and science, and his co-founder, Ms. Jenny Lynn, a business executive with twenty years of experience launching new ventures. Benchmark, Icon Ventures, Intrinsic Capital Partners, Main Street Advisors, NFP Ventures, and individual investors have funded the Company. | $20M / Venture - Series Unknown / Sep 03, 2021 | |
|
|
Treez is an enterprise cloud commerce platform that streamlines retail and supply chain operations within the cannabis market. Through its innovative technology for retailers and brands, the company provides a robust breadth and depth of software solutions required to operate a successful modern dispensary.Solutions include point of sale,dispensary inventory management, and omnichannel sales capabilities all on a mission-critical platform that ensures regulatory compliance across every supply chain transaction. The innovative platform also connects essential brands with their retailers through a centralized brand catalog with real-time market insights. The extensible open API platform provides smooth integration into a variety of best-of-breed solutions, including CRM, marketplace, and data analytics across the partner ecosystem, giving retailers everything they need to grow their business. | $13M / Series B / Sep 17, 2020 | |
|
|
Hound Labs is a breath technology company that has developed ultra-sensitive technology for non-invasive breath measurement. Utilizing this groundbreaking technology, the HOUND MARIJUANA BREATHALYZER is the world’s first breathalyzer to rapidly, accurately, and inexpensively measure recent marijuana use and alcohol in a person’s breath. The HOUNDBREATHALYZER is intended for law enforcement, employer, and insurance purposes only. Founded in 2014, the Oakland-based company was created by Dr. Mike Lynn, an ER physician, reserve deputy sheriff, and former venture capitalist, his co-founder, Mr. Kuni Oh, a patent attorney with a deep background in engineering and science, and his co-founder, Ms. Jenny Lynn, a business executive with twenty years of experience launching new ventures. Benchmark, Icon Ventures, Intrinsic Capital Partners, Main Street Advisors, NFP Ventures, and individual investors have funded the Company. | $30M / Series D / Aug 27, 2019 | |
|
|
Treez is an enterprise cloud commerce platform that streamlines retail and supply chain operations within the cannabis market. Through its innovative technology for retailers and brands, the company provides a robust breadth and depth of software solutions required to operate a successful modern dispensary.Solutions include point of sale,dispensary inventory management, and omnichannel sales capabilities all on a mission-critical platform that ensures regulatory compliance across every supply chain transaction. The innovative platform also connects essential brands with their retailers through a centralized brand catalog with real-time market insights. The extensible open API platform provides smooth integration into a variety of best-of-breed solutions, including CRM, marketplace, and data analytics across the partner ecosystem, giving retailers everything they need to grow their business. | $11.5M / Series A / Sep 10, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Intrinsic Capital Partners invest in?
Intrinsic Capital Partners invests primarily in Biotechnology, Health Care and Cannabis startups, most often at Series A and Venture - Series Unknown stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Intrinsic Capital Partners's check size?
Intrinsic Capital Partners typically joins rounds of $12M–$20M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Intrinsic Capital Partners participates in.
How do I contact Intrinsic Capital Partners?
Public channels for Intrinsic Capital Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Intrinsic Capital Partners?
The team at Intrinsic Capital Partners includes Cornelius Merlini (Managing Partner & Founder), Gerald F Stahlecker (Partner & Founder) and Howard Goodwin (Partner & Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!